US WorldMeds gets FDA greenlight for drug previously pulled for safety concerns

US WorldMeds LLC received final approval to reintroduce an irritable bowel syndrome drug that was pulled from the market in 2007 because of patient safety concerns. The Louisville special specialty pharmaceutical company said the Food and Drug Administration had given it final approval to market tegaserod, which is branded as Zelnorm, for the treatment of irritable bowel syndrome with constipation, or IBS-C, in women under 65. The approval was received thro ugh Sloan Pharma, S.a.r.l., a subsidiary…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news